Pascal Biosciences Provides Corporate Update for First Quarter of 2019
23 Abril 2019 - 7:30AM
Pascal Biosciences Inc. (
TSX.V:PAS) (“Pascal” or
the “Company”), a drug discovery and development company, today
provided a corporate update for the first quarter of 2019.
“We’ve made significant strides since the start
of 2019, and these advancements position Pascal well for the
future,” said Dr. Patrick Gray, CEO of Pascal. “We have advanced
our cannabinoid program into clinical testing, our glioblastoma
program has made excellent progress, and we have deepened our
corporate leadership, all to support the continued growth of this
Company.”
First quarter highlights include:
Glioblastoma Program – Advancement Towards Clinical
Trials
Great progress has been made for Pascal’s
clinical candidate for glioblastoma, PAS-403, as it advances toward
clinical trials. An efficient manufacturing process has been
developed. Studies continue to support the use of PAS-403 for
testing in glioblastoma patients: the compound is active against
human glioblastoma cells in culture, accumulates in the brain, has
a good safety profile against other targets, and has synergistic
activity with standard of care in an animal model. A clinical plan
has been developed for testing PAS-403 in glioblastoma
patients.
Clinical – Testing of Cannabinoids in Human
Subjects
In January, Pascal announced the initiation of
testing of cannabinoids in human subjects for its immune
stimulatory program in cancer. Pascal has extensively studied
nearly 400 different cannabinoids in a variety of immune
stimulatory assays and identified specific natural cannabinoids
that have potent activity and a good safety profile. Pascal plans
to extend these studies during 2019 with a potent cannabinoid to
evaluate immune stimulatory activity.
Patents – Filing of international patent for further
therapeutic indications
In January, Pascal filed an international patent
to protect its discoveries around certain cannabinoids that
increase the immunogenicity of cancer cells. This patent
application is covered by the Patent Cooperation Treaty that
includes 151 countries and covers all major pharmaceutical markets
worldwide.
Partnering – Partnership with MITACS for multi-year
research project
In March, Pascal announced a partnership with
Mitacs for a multi-year cancer research project at the University
of British Columbia. Mitacs, a not-for-profit organization
that fosters growth and innovation, will provide equal funding for
research efforts at UBC that will directly support Pascal’s leading
cancer development programs. The research project will be directed
by Dr. Wilfred Jefferies at the Michael Smith Laboratories at UBC.
Dr. Jefferies, the scientific founder of Pascal, was the first
scientist to discover specific cannabinoids that can increase the
immune recognition of both mouse and human cancer cells. The
project will support the ongoing advancement of the PAS-393
program, which the Company believes may enhance the effectiveness
of checkpoint inhibitors.
Leadership – Appointment of Carl Weissman
In April, Pascal announced that biotech industry
veteran Carl Weissman has joined the Company in the role of acting
President. Weissman most recently served as a biotech investment
advisor for Lightspeed Venture Partners. His prior
experiences include serving as consulting CEO of OSS Healthcare, a
joint venture of MPM Capital and Novartis Oncology and co-founder,
CEO and chairman at Accelerator Corporation, as well as all 10
companies invested in and managed by Accelerator. He also
previously served at MPM Capital, Centagenetix and Prolinx,
Inc.
About Pascal Biosciences Inc.
Pascal Biosciences is a biotechnology company
focused on advancing innovative approaches for the treatment of
cancer including cannabinoid-based therapeutics and targeted
therapies. The company’s leading portfolio comprises a small
molecule therapeutic, PAS-403, that is advancing into clinical
trials for the treatment of glioblastoma, and PAS-393, an
immuno-stimulatory cannabinoid to be used in combination with
checkpoint inhibitor therapy. In addition, Pascal Biosciences is
developing a B-cell targeted antibody for acute lymphoblastic
leukemia. For more information, visit
www.pascalbiosciences.com.
Investors: invest@pascalbiosciences.com
Media Contact: Julie
Rathbuninfo@pascalbiosciences.com Tel: 206-769-9219
DISCLAIMER Certain statements in this press
release contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including
without limitation statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially
different from any future results, events or developments express
or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to
revise or update such forward- looking statements and information
to reflect subsequent events or circumstances, except as required
by law.
“Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release”
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024